Page last updated: 2024-11-11

saralasin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6324663
CHEMBL ID938
CHEBI ID135894
SCHEMBL ID23
MeSH IDM0019423

Synonyms (38)

Synonym
saralasin
NCGC00166135-01
saralasin [inn:ban]
(1-(n-methylglycin) 5-l-valin, 8-l-alanin)angiotensin ii
sar-arg-val-tyr-val-his-pro-ala
saralasina [inn-spanish]
saralasine [inn-french]
angiotensin ii, 1-(n-methylglycine)-5-l-valine-8-l-alanine-
saralasinum [inn-latin]
n-(1-(n-(n-(n-(n-(n2-(n-methylglycly)-l-arginyl)-l-valyl)-l-tyrosyl)-l-valyl)-l-histidyl)-l-prolyl)-l-alanine
NCGC00167316-01
CHEBI:135894
34273-10-4
CHEMBL938 ,
1-sar-8-ala-angiotensin ii
(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrol
(s)-2-((s)-1-((s)-2-((s)-2-((s)-2-((s)-2-((s)-5-(diaminomethyleneamino)-2-(2-(methylamino)acetamido)pentanamido)-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylbutanamido)-3-(1h-imidazol-5-yl)propanoyl)pyrrolidine-5-carboxamido)propanoic acid
bdbm50009338
sar-arg-val-tyr-val-his-pro-ala (sarlasin)
[sar1-arg2-val3-tyr4-val5-his6-pro7-ala8]
dtxcid0026549
tox21_112332
cas-34273-10-4
dtxsid2046549 ,
saralasinum
saralasina
unii-h2afv2he66
h2afv2he66 ,
saralasine
SCHEMBL23
(sar1,val5,ala8)-angiotensin ii
AKOS024456428
(s)-2-((s)-1-((6s,9s,12s,15s,18s)-18-((1h-imidazol-4-yl)methyl)-6-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9,15-diisopropyl-4,7,10,13,16-pentaoxo-2,5,8,11,14,17-hexaazanonadecane)pyrrolidine-2-carboxamido)propanoic acid
Q410298
DB06763
bdbm50229504
CS-0021297
HY-P0205

Research Excerpts

Overview

Saralasin acts as an agonist at central AII receptors in rats maintained on a high sodium intake. It is a highly soluble and stable AII antagonist with a relatively short half-life.

ExcerptReferenceRelevance
"saralasin acts as an agonist at central AII receptors in rats maintained on a high sodium intake."( Will chronic intracerebroventricular saralasin infusion produce selective blockade of brain angiotensin II receptors in the rat?
Bruner, CA; Fink, GD; Weaver, JM, 1983
)
1.26
"Saralasin is a highly soluble and stable AII antagonist with a relatively short half-life; therefore, its effects are rapidly reversible when administered i.v. "( Preclinical pharmacology of saralasin.
Castellion, AW; Fulton, RW, 1979
)
2
"Saralasin is a partial agonist."( Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium-restricted normal man.
Brown, C; Hollenberg, NK; Mersey, JH; Williams, GH, 1978
)
0.98

Effects

Saralasin has a protective effect against glycerol-induced acute renal failure only when volume is replaced concomitantly. Saralasin is of great value in simply and reliably demonstrating the presence or absence of an angiotensinogenic component.

ExcerptReferenceRelevance
"5. Saralasin has a protective effect against glycerol-induced acute renal failure only when volume is replaced concomitantly."( Effect of saralasin and serum in myohaemoglobinuric acute renal failure of rats.
Bauereiss, K; Gross, F; Hofbauer, KG; Konrads, A, 1978
)
1.17
"5. Saralasin has a protective effect against glycerol-induced acute renal failure only when volume is replaced concomitantly."( Effect of saralasin and serum in myohaemoglobinuric acute renal failure of rats.
Bauereiss, K; Gross, F; Hofbauer, KG; Konrads, A, 1978
)
1.17
"Saralasin has been of great value in simply and reliably demonstrating the presence or absence of an angiotensinogenic component in a large group of hypertensive patients."( The use of saralasin in the recognition of angiotensinogenic hypertension.
Anderson, GH; Dalakos, TG; Streeten, DH, 1976
)
1.37

Actions

Saralasin did not lower BP in DOCA-salt hypertensive rats. It did not inhibit the recovery from hemorrhagic shock produced by large volume isotonic saline reexpansion.

ExcerptReferenceRelevance
"Saralasin caused an increase of percent distribution of CO to the kidneys."( Effect of vasopressin antagonist and saralasin on regional blood flow following hemorrhage.
Pang, CC, 1983
)
1.26
"2 Saralasin did not lower BP in DOCA-salt hypertensive rats."( Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor.
Casals-Stenzel, J; Lever, AF; Millar, JA; Morton, JJ; Riegger, AJ; Tree, M, 1979
)
0.82
"Saralasin did not inhibit the recovery from hemorrhagic shock produced by large volume isotonic saline reexpansion."( Central angiotensinergic system and hypertonic resuscitation from severe hemorrhage.
Baena, RC; Loureiro, MI; Rocha e Silva, M; Velasco, IT, 1990
)
1
"Saralasin produced an increase in preglomerular diameters which was largest (37 +/- 11%) in the interlobular artery (there was no dilation in the afferent arteriole near the glomerulus), an increase in postglomerular diameters which was largest (17 +/- 4%) in the efferent arteriole near the glomerulus, and an increase in blood flow (19 +/- 4%)."( Angiotensin II control of the renal microcirculation: effect of blockade by saralasin.
Kücherer, H; Parekh, N; Steinhausen, M; Weis, S; Wiegman, DL; Wilhelm, KR, 1986
)
1.22

Treatment

Saralasin treatment beginning 20 min posthemorrhage produced a pattern in which neither TRBF nor cortical blood flow was significantly reduced by the hemorrhage. Treatment with saralasin, 5 mug dissolved in 1 mul saline followed by 9 mul saline in each lateral cerebral ventricle, did not influence tidal volume, but markedly reduced tidal volume variability.

ExcerptReferenceRelevance
"Saralasin treatment beginning 20 min posthemorrhage produced a pattern in which neither TRBF nor cortical blood flow was significantly reduced by the hemorrhage."( Angiotensin II and alpha-adrenergic control of the intrarenal circulation in hemorrhage.
Hock, CE; Levin, JI; Neiberger, RE; Passmore, JC, 1982
)
0.99
"Saralasin-treated ovulations were 6.6 +/- 1.3 (mean + SEM) compared with 18.6 +/- 3.9, p < 0.02. "( The angiotensin II antagonist saralasin inhibits ovulation in the perfused rat ovary.
Butler, TA; LeMaire, WJ; Mukaida, T; Peterson, CM; Woessner, JF; Zhu, C, 1993
)
2.02
"Saralasin pretreatment prior to nicotine resulted only in a significantly (p less than 0.01) greater OC flow than nicotine only."( Mechanisms mediating canine renal vasoconstriction induced by nicotine infusion.
Hock, CE; Passmore, JC, 1985
)
0.99
"Treatment with saralasin, 5 mug dissolved in 1 mul saline followed by 9 mul saline in each lateral cerebral ventricle, did not influence tidal volume, but markedly reduced tidal volume variability (p=0.0005), as compared to saline injections (10 mul)."( Intracerebroventricular administration of the angiotensin II receptor antagonist saralasin reduces respiratory rate and tidal volume variability in freely moving Wistar rats.
Annerbrink, K; Eriksson, E; Hedner, J; Olsson, M, 2004
)
0.89
"Pretreatment with saralasin significantly prevented the increase in lung tissue myeloperoxidase activity, EMAP II, and lung epithelial apoptosis."( Angiotensin II receptor blockade inhibits pneumocyte apoptosis in experimental meconium aspiration.
Aho, H; Kääpä, P; Laine, J; Lehtonen, J; Lukkarinen, H; Vidyasagar, D; Zagariya, A, 2004
)
0.65
"Pretreatment with saralasin or losartan significantly prevented the increase of TUNEL positivity in pneumocytes, but had no effect on the amount of neutrophil influx or total injury score in lavaged lungs."( Angiotensin II receptor inhibition prevents pneumocyte apoptosis in surfactant-depleted rat lungs.
Aho, H; Kääpä, PO; Laine, J; Lukkarinen, HP; Vidyasagar, D; Zagariya, A, 2005
)
0.65
"Pretreatment with saralasin, an AII antagonist, effectively blocked (100%) the actions of AII (n = 5)."( Differential effects of angiotensin II on the activities of suprachiasmatic neurons in rat brain slices.
Pan, JT; Tang, KC, 1995
)
0.61
"Pretreatment with saralasin (Sar, 10(-10) M), a specific angiotensin II (ANG II) antagonist, into the median preoptic nucleus (MnPO) diminished the excitatory response to the osmotic stimulation in 13 of 17 cells tested."( Angiotensinergic modulation of osmotic activation of neurosecretory neurons.
Hayashi, Y; Shimamune, S; Tanaka, J; Watai, T, 1997
)
0.62
"Pretreatment with saralasin and sarmesin antagonized the Ang II effect on the latency to seizures."( Participation of angiotensin receptors in acute hypoxia in mice. I. Effects of angiotensin peptide receptor ligands saralasin and sarmesin.
Georgiev, V; Opitz, M,
)
0.66
"Pretreatment with saralasin, losartan, and CGP42112A injected into the PVN caused shifts to the right of the concentration-response curves, but the losartan concentrations were disproportionately greater compared with salarasin or CGP42112A."( Renal effects of angiotensin II receptor subtype 1 and 2-selective ligands injected into the paraventricular nucleus of conscious rats.
de Arruda Camargo, LA; Saad, WA, 1999
)
0.63
"Treatment with saralasin, however, resulted in complete inhibition of bFGF mRNA expression in the presence of both LH and angiotensin II."( Angiotensin II inhibits luteinizing hormone-stimulated cholesterol side chain cleavage expression and stimulates basic fibroblast growth factor expression in bovine luteal cells in primary culture.
Magness, RR; Simpson, ER; Stirling, D; Stone, R; Waterman, MR, 1990
)
0.62
"Rats treated with saralasin presented a delay in the onset of hypertension right after coarctation but slowly attained values similar to those for control rats."( Acute aortic coarctation hypertension: role of vasopressin and angiotensin II.
Salgado, HC; Salgado, MC, 1989
)
0.6

Bioavailability

ExcerptReferenceRelevance
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The dose-response relationship of the mesenteric resistance vessels to vasopressin was studied in anesthetized laparotomized cats before and after hypophysectomy. We found that saralasin or DuP 753, but not the kinin antagonist, displaced the dose- response curve to the right. This may have been mediated by vascular alpha-adrenoceptors.

ExcerptRelevanceReference
" Each agent was evaluated at concentrations ranging from 10-8 to 10-5 m and three different dose-response curve patterns were observed: (1) Metoprolol, acebutolol, labetalol, and d-propranolol had no effect on isoproterenol-stimulated renin release at any concentration, whereas pindolol and bufuralol demonstrated minimal inhibition at 10-5 m only."( Effect of beta-blocking agents and angiotensin II on isoproterenol-stimulated renin release from rat kidney slices.
Capponi, AM; Gourjon, M; Vallotton, MB, 1977
)
0.26
" We have compared the effects of an angiotensin antagonist (saralasin) and an alpha-adrenergic blocking agent (phenoxybenzamine) in supramaximal dosage on cardiac output, total peripheral resistance, and venous tone in rabbits rendered hypovolemic by restriction of sodium intake, supplemented by a furosemide-induced diuresis 48 h prior to study."( Cardiovascular responses to blockade of angiotensin and alpha-adrenergic receptors.
Borucki, LJ; Hollenberg, NK; Levenson, D, 1978
)
0.5
" With increasing concentrations of angiotensin II logarithmic dose-response curves for aldosterone and cyclic AMP production were similar."( Adenosine 3':5'-cyclic monophosphate production and steroidogenesis by isolated rat adrenal glomerulosa cells. Effects of angiotensin II and [Sar 1,Ala 8]angiotensin II.
Bing, RF; Schulster, D, 1978
)
0.26
"Evidence of selective inhibition, differences in dose-response relationships, and cross-tachyphylaxis studies suggest that separate receptors and/or mechanisms may be involved in responses to angiotensin (Ang), [Sar1]Ang II, and Ang III (= des-Asp1-Ang II)."( Demonstration of different contractile mechanisms for angiotensin II and des-Asp1-angiotensin II in rabbit aortic strips.
Ackerly, JA; Moore, AF; Peach, MJ, 1977
)
0.26
"The dose-response relationship of the mesenteric resistance vessels to vasopressin was studied in anesthetized laparotomized cats before and after hypophysectomy and again during the plateau phase of the response to a prolonged infusion of [Sar1-Ala8] angiotensin II (saralasin), a competitive antagonist of angiotensin II."( Hypophysectomy and saralasin on mesenteric vasoconstrictor response to vasopressin.
McNeill, JR; Pang, CC; Wilcox, WC, 1979
)
0.77
" This may have been mediated by vascular alpha-adrenoceptors because log dose-response curves of saralasin-induced increases in systolic pressure were shifted to the right in a parallel fashion after phentolamine."( The pressor actions of noradrenaline, angiotensin II and saralasin in chronic autonomic failure treated with fludrocortisone.
Bannester, R; Davies, B; Sever, P; Wilcox, C, 1979
)
0.72
" Dose-response curves for AII and the (2-8) peptide [angiotensin III (AIII)] indicate that AII is a more potent inhibitor of renin release than is AIII."( Inhibition of renin release from rat kidney slices by the angiotensins.
Naftilan, AJ; Oparil, S, 1978
)
0.26
" In normotensives with normal plasma renin activity saralasine in the usual dosage (4."( [The influence of saralasine on blood pressure and renal function in Bartter's syndrome and decompensated hepatic cirrhosis (author's transl)].
Dürr, H; Klaus, D; Lange, H; Witzgall, H; Zehner, J, 1976
)
0.84
" These findings confirm and extend earlier studies of angiotensin II/arterial pressure and angiotensin II/aldosterone dose-response curves."( The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
Brown, JJ; Brown, WC; Fraser, R; Lever, AF; Morton, JJ; Robertson, JI; Rosei, EA; Trust, PM, 1976
)
0.52
") caused a rightward displacement of dose-response curves to Ang II or Ang III in both the mesenteric and renal vasculature."( A comparison of the characteristics of angiotensin receptors in the renal and mesenteric vascular beds of the anesthetized cat.
Clark, KL; Drew, GM; Robertson, MJ, 1992
)
0.28
" Pretreatment with the angiotensin-converting enzyme (ACE) inhibitor captopril markedly enhanced the effect of BK, such that the dose-response curve shifted significantly to the left in all three strains."( Interaction of bradykinin and angiotensin in the regulation of blood pressure in conscious rats.
Kerkhoff, J; van den Buuse, M, 1991
)
0.28
" In separate groups of rats, the log dose-response curve for bolus intravenous injection of AII was shifted to the right by SQ-29,548 while that for PE was unaffected."( Thromboxane mediation of the pressor response to infused angiotensin II.
Welch, WJ; Wilcox, CS, 1990
)
0.28
" Captopril (10(-6) M) and SnoCap (10(-6) M) equally inhibited contraction to angiotensin I, inducing a 50-fold shift in the dose-response curve."( S-nitrosocaptopril. II. Effects on vascular reactivity.
Andon, N; Cooke, JP; Loscalzo, J, 1989
)
0.28
" The dose-response relations for the increase in blood pressure of rats receiving endothelin were comparable with those of rats receiving angiotensin II."( Characteristics of pressor response to endothelin in spontaneously hypertensive and Wistar-Kyoto rats.
Goto, K; Ishikawa, T; Ito, I; Kimura, S; Masaki, T; Miyauchi, T; Sugishita, Y; Tomobe, Y; Yanagisawa, M, 1989
)
0.28
" Dose-response curves for angiotensins II and III in the rat isolated uterus, portal vein and aorta, in the absence and presence of the antagonist [Sar1Ile8]ANG II, have been analyzed by methods which detect cooperativity."( Methods for analyzing and interpreting cooperativity in dose-response curves--I. Antagonist effects on angiotensin receptors in smooth muscle.
Moore, GJ; Scanlon, MN, 1989
)
0.28
" The dose-response curves for hAI and sAI were similar and revealed that hAI and sAI were about one-tenth as potent as hAII in stimulating ACTH release."( Stimulation by angiotensins I and II of ACTH release from goldfish pituitary cell columns.
Fryer, JN; Weld, MM, 1987
)
0.27
"min-1 did not affect the change in renal blood flow produced by ANG II, indicating that at this dosage the antagonist did not leave the mesenteric circulation in pharmacologically significant quantities."( Local control of mesenteric blood flow by the renin-angiotensin system.
Levens, NR; Suvannapura, A, 1988
)
0.27
" Dose-response curves showed that rats lacking area postrema drank more saline in response to systemic angiotensin than sham operated animals."( Actions of angiotensin on area postrema of the rat.
Watson, WE, 1986
)
0.27
" The cardiovascular effects elicited by microinjections of the peptide exhibit complicated dose-response relationships."( Cardiovascular effects of microinjections of angiotensin II into the nucleus tractus solitarii.
Healy, DP; Printz, MP; Rettig, R, 1986
)
0.27
" Due to tachyphylaxis second dose-response run was used for comparison."( Kallikrein potentiation of angiotensin I-induced contraction on isolated mesenteric artery.
Larsson-Backstrom, C, 1983
)
0.27
" Particular attention has been paid to peripheral plasma concentrations of angiotensin II in different circumstances; angiotensin II infusion has been combined with radioimmunoassay to construct angiotensin II/blood pressure dose-response curves."( Angiotensin II and renal hypertension in dog, rat and man: effect of converting enzyme inhibition.
Atkinson, AB; Brown, JJ; Fraser, R; Lever, AF; Morton, JJ; Riegger, AJ; Robertson, JI, 1980
)
0.26
" To establish whether the sensitivity to exogenous bradykinin was affected by the presence of angiotensin, vasodepressor dose-response curves to injected bradykinin were performed in conscious rats before and during a 1-h infusion of angiotensin I (30 ng/min), angiotensin II (30 and 300 mg/min), and [Sar2,Ala8]angiotensin II (5 micrograms/min)."( Evidence for bradykinin potentiation by angiotensin congeners in conscious rats.
Brunner, H; Gavras, H; Textor, SC, 1981
)
0.26
" With the size of isolated glomeruli as the index, we have demonstrated identical dose-response relationships for graded concentrations (10(-13) to 10(-3) g/liter) of angiotensin II (AII) and angiotensin III (AIII)."( Angiotensin receptors in glomeruli differ from those in renal arterioles.
Caldicott, WJ; Hollenberg, NK; Margulies, SS; Taub, KJ, 1981
)
0.26
" The log dose-response curve for ACTH release by angiotensin II was shifted to the right in a parallel fashion by saralasin 10 nmol/l, suggesting competitive antagonism."( Angiotensin II stimulates the release of ACTH from dispersed rat anterior pituitary cells.
Besser, GM; Gaillard, RC; Gillies, G; Grossman, A; Rees, LH, 1981
)
0.47
" Dose-response studies indicated a rank order of CRA as follows: CRF greater than AVP greater than OXY greater than AII = AIII."( Angiotensin II and ACTH release: site of action and potency relative to corticotropin releasing factor and vasopressin.
Negro-Vilar, A; Spinedi, E, 1983
)
0.27
" Pressor responsiveness was evaluated acutely on the basis of dose-response curves (0."( Pressor responses of rats to vasopressin: effect of sodium, angiotensin, and catecholamines.
Brunner, HR; Burnier, M, 1983
)
0.27
" The slopes of the two dose-response curves were very similar (-14."( The effect of saralasin in the chronically cannulated ewe in the early puerperium.
Broughton Pipkin, F; Turner, SR; Wallace, C, 1984
)
0.63
" Dose-response curves for All-induced contractions of rat aortic strips demonstrated a decrease in All-midrange sensitivity during development."( Relationship between developmental changes in angiotensin II-induced contractions and stimulation of phosphatidylinositol labeling of rat aorta.
Rutledge, CO; Schoepp, DD, 1984
)
0.27
" By the example of the peptides saralasin, gonadorelin and protirelin and the corresponding dosage forms, the suitability of the technique for identification, purity and stability tests, as well as for analytical work, is demonstrated."( [Capillary isotachophoresis--a new method in drug analysis. 1. Analytic capillary isotachophoresis of the peptide drugs saralasin, gonadorelin and protirelin].
Jannasch, R, 1983
)
0.76
" Captopril was infused intravenously in graded dosage from 10 to 3,000 microgram/kg, and renal blood flow measured with an electromagnetic flowmeter."( Specificity of renal vasodilation with captopril: saralasin prevents the response in the DOCA-treated, salt-loaded rabbit.
Hollenberg, NK; Passan, DR, 1982
)
0.52
" We can look forward to newer agents that are efficacious as monotherapy and on a daily or twice daily dosage regimen for the treatment of the vast majority of hypertensive patients."( Newer antihypertensive agents.
Thind, GS, 1980
)
0.26
"The effect of an intravenous infusion of saralasin in a rising dosage on blood pressure, central haemodynamics, forearm blood flow and venous distensibility was tested in 11 subjects with chronic non-uraemic renal disease."( Effect of the angiotensin antagonist saralasin on hemodynamics in hypertensive non-uraemic chronic renal disease.
Bahlmann, J; Brod, J; Cachovan, M; Hubrich, W; Pretschner, D, 1980
)
0.8
" Saralasin and its analogues allowed visualization, for the first time, of complete angiotensin II/effector (especially blood pressure) dose-response curves."( Blockade of the renin-angiotensin system.
Charles, CJ; Crozier, IG; Espiner, EA; Ikram, H; Nicholls, MG; Rademaker, MJ; Richards, AM; Yandle, TG, 1994
)
1.2
" First, in control hearts, dose-response curves were obtained for single ANP dosages of 1-100 nmol."( Interrelation of coronary effects of atrial natriuretic peptide and the renin-angiotensin system in the isolated perfused rat heart.
Bauer, WR; Ertl, G; Neubauer, S; Obitz, G, 1994
)
0.29
" We found that saralasin or DuP 753, but not the kinin antagonist, displaced the dose-response curve to the right."( Oxytocic effect of trypsin on the isolated rat uterus.
Castillo, G; Esteban, S; Orce, G, 1994
)
0.64
" Perfusions with both saralasin and angiotensin II and dose-response evaluations were performed."( The angiotensin II antagonist saralasin inhibits ovulation in the perfused rat ovary.
Butler, TA; LeMaire, WJ; Mukaida, T; Peterson, CM; Woessner, JF; Zhu, C, 1993
)
0.89
" Dose-response evaluations showed a progressive inhibition of ovulation at 10(-8) to 10(-6) mol/L."( The angiotensin II antagonist saralasin inhibits ovulation in the perfused rat ovary.
Butler, TA; LeMaire, WJ; Mukaida, T; Peterson, CM; Woessner, JF; Zhu, C, 1993
)
0.57
" Intracellular administration of CV11947 or PD 123319 right shifted the dose-response curve about 1000 fold or 20 fold, respectively."( Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta.
Brailoiu, E; de Zeeuw, D; Filipeanu, CM; Nelemans, SA; Tica, A; Toma, CP, 1999
)
0.3
" However, all ARBs caused less than maximal inhibition after the highest dose, thus causing a U-shaped dose-response curve with respect to sympatho-inhibition."( Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.
Balt, JC; Mathy, MJ; Nap, A; Pfaffendorf, M; van Zwieten, PA, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.00170.00040.15553.8000AID37832
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00170.00040.13343.8000AID37832
Type-1 angiotensin II receptorHomo sapiens (human)IC50 (µMol)0.00060.00020.09323.6000AID1285615; AID1336307; AID340237; AID346402; AID566244; AID751898; AID752259
Type-1 angiotensin II receptorHomo sapiens (human)Ki0.00020.00020.18374.7000AID1169022; AID346402; AID751898
Type-2 angiotensin II receptorHomo sapiens (human)IC50 (µMol)0.00080.00010.02890.2000AID346403; AID38149; AID566245
Type-2 angiotensin II receptorHomo sapiens (human)Ki0.00030.00020.56507.7790AID1169023; AID1277889; AID346403
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)EC50 (µMol)0.00670.00130.03390.2040AID1634589; AID1634591
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)Kd0.00020.00000.00270.0100AID39329; AID39330
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)Kd0.00020.00000.00020.0002AID39329; AID39330
Type-1 angiotensin II receptorHomo sapiens (human)EC50 (µMol)5.00550.00050.01350.0676AID1634585; AID1634587
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)Kd0.00020.00000.00020.0002AID39329; AID39330
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
regulation of cell growthType-1 angiotensin II receptorHomo sapiens (human)
kidney developmentType-1 angiotensin II receptorHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionType-1 angiotensin II receptorHomo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationType-1 angiotensin II receptorHomo sapiens (human)
Rho protein signal transductionType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationType-1 angiotensin II receptorHomo sapiens (human)
regulation of vasoconstrictionType-1 angiotensin II receptorHomo sapiens (human)
calcium-mediated signalingType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityType-1 angiotensin II receptorHomo sapiens (human)
low-density lipoprotein particle remodelingType-1 angiotensin II receptorHomo sapiens (human)
regulation of renal sodium excretionType-1 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
regulation of cell population proliferationType-1 angiotensin II receptorHomo sapiens (human)
symbiont entry into host cellType-1 angiotensin II receptorHomo sapiens (human)
regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of protein metabolic processType-1 angiotensin II receptorHomo sapiens (human)
cell chemotaxisType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
blood vessel diameter maintenanceType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesisType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of CoA-transferase activityType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processType-1 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
blood vessel remodelingType-2 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by circulatory renin-angiotensinType-2 angiotensin II receptorHomo sapiens (human)
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressureType-2 angiotensin II receptorHomo sapiens (human)
brain renin-angiotensin systemType-2 angiotensin II receptorHomo sapiens (human)
cell surface receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messengerType-2 angiotensin II receptorHomo sapiens (human)
brain developmentType-2 angiotensin II receptorHomo sapiens (human)
regulation of blood pressureType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of heart rateType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of cell growthType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityType-2 angiotensin II receptorHomo sapiens (human)
regulation of metanephros sizeType-2 angiotensin II receptorHomo sapiens (human)
exploration behaviorType-2 angiotensin II receptorHomo sapiens (human)
nitric oxide-cGMP-mediated signalingType-2 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
vasodilationType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of neurotrophin TRK receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
neuron apoptotic processType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of metanephric glomerulus developmentType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesisType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-2 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
angiotensin type I receptor activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingType-1 angiotensin II receptorHomo sapiens (human)
bradykinin receptor bindingType-1 angiotensin II receptorHomo sapiens (human)
protein heterodimerization activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-2 angiotensin II receptorHomo sapiens (human)
protein bindingType-2 angiotensin II receptorHomo sapiens (human)
receptor antagonist activityType-2 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-2 angiotensin II receptorHomo sapiens (human)
plasma membraneType-2 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID39329Antagonistic effect against Angiotensin II receptor in rabbit aortic strip1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID174203Variation in mean arterial pressure produced by angiotensin II, 20 min after administration (dose 10 ug/kg/min) in rats; 78/51989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.
AID174214Variation in mean arterial pressure, produced by angiotensin II upon administration at 10 ug/kg/min in rats1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.
AID37676Binding affinity for Angiotensin II receptor, type 1 measured by ability to displace [125I]- A II from its specific binding site in rat liver membrane1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
AID1169023Binding affinity to AT2 receptor (unknown origin)2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
Saralasin and Sarile Are AT2 Receptor Agonists.
AID174201Variation in mean arterial pressure produced by angiotensin II, 10 min after administration (dose 10 ug/kg/min) in rats; 50/51989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.
AID173009Tested in vivo on the angiotensin II induced rise of blood pressure after intravenous administration of 1.25 ug/kg in conscious rats1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID167649Antagonistic activity through inhibition of A II induced contractions on rabbit aortic strips1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
AID566245Inhibition of human angiotensin II AT2 receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID173013Tested in vivo on the angiotensin II induced rise of blood pressure after intravenous administration of 5 ug/kg in conscious rats1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID566244Inhibition of human angiotensin II AT1 receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID1169022Binding affinity to AT1 receptor (unknown origin)2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
Saralasin and Sarile Are AT2 Receptor Agonists.
AID752259Binding affinity to human angiotensin AT1 receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID174206Variation in mean arterial pressure produced by angiotensin II, 40 min after administration (dose 10 ug/kg/min) in rats; 96/41989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.
AID31303Inhibitory activity as antagonist of AII on guinea pig ileum1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of angiotensin II analogues containing a Val-His replacement, Val psi[CH(CONH2)NH]His.
AID346403Displacement of radiolabeled saralasin from human AT2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID346402Displacement of radiolabeled saralasin from human AT1 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID195479Time course for AII (6 ng) induced pressor response in rats to return to 50% of pretreatment level after a bolus injection of 30 microg1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Long-acting angiotensin II inhibitors containing hexafluorovaline in position 8.
AID1169025Antagonist activity at AT2 receptor in rat and mouse hybridoma NG108-15 cells assessed as reduction in angiotensin-2-induced neurite outgrowth at 100 nM after 3 days by phase contrast microscopy2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
Saralasin and Sarile Are AT2 Receptor Agonists.
AID173012Tested in vivo on the angiotensin II induced rise of blood pressure after intravenous administration of 20 ug/kg in conscious rats1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID1277888Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
AID195476Time course for AII (6 ng) induced pressor response in rats to return to 50% of pretreatment level after a bolus injection of 10 microg1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Long-acting angiotensin II inhibitors containing hexafluorovaline in position 8.
AID174343Variation in mean arterial pressure produced by angiotensin II, 60 min after administration (dose 10 ug/kg/min) in rats; 94/61989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.
AID751898Binding affinity to human AT1 receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID31277The compound was tested for its inhibitory activity as antagonist of AI on guinea pig ileum1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of angiotensin II analogues containing a Val-His replacement, Val psi[CH(CONH2)NH]His.
AID39052Displacement of [3H]Angiotensin II (300 ng/mL) from rabbit adrenal cortex1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of angiotensin II analogues containing a Val-His replacement, Val psi[CH(CONH2)NH]His.
AID1277889Binding affinity to type-2 angiotensin-2 receptor (unknown origin)2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
AID195477Time course for AII (6 ng) induced pressor response in rats to return to 50% of pretreatment level after a bolus injection of 100 microg1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Long-acting angiotensin II inhibitors containing hexafluorovaline in position 8.
AID1169021Agonist activity at AT2 receptor in rat and mouse hybridoma NG108-15 cells assessed as induction of neurite outgrowth at 100 nM after 3 days by phase contrast microscopy2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
Saralasin and Sarile Are AT2 Receptor Agonists.
AID340237Inhibition of human AT1 receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID38149In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
AID1336307Displacement of [125I][Sar1,Ile8]-AT2 from human recombinant AT1 receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID173011Tested in vivo on the angiotensin II induced rise of blood pressure after intravenous administration of 2.5 ug/kg in conscious rats1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID174209Variation in mean arterial pressure produced by angiotensin II, 5 min after administration (dose 10 ug/kg/min) in rats; 29/51989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.
AID37832In vitro binding affinity to the angiotensin II receptor, type 1 in rat liver1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
AID173010Tested in vivo on the angiotensin II induced rise of blood pressure after intravenous administration of 10 ug/kg in conscious rats1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID1285615Displacement of [125I][Sar, Ile]-ATII from human recombinant AT1 receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID39330Antagonistic effect against Angiotensin II receptor in zona glomerulosa1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis of angiotensin II antagonists with variations in position 5.
AID1169024Agonist activity at AT2 receptor in rat and mouse hybridoma NG108-15 cells assessed as induction of neurite outgrowth at 100 nM after 3 days in presence of 1 uM AT2 receptor antagonist PD 123,319 by phase contrast microscopy2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
Saralasin and Sarile Are AT2 Receptor Agonists.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,410)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901010 (71.63)18.7374
1990's316 (22.41)18.2507
2000's64 (4.54)29.6817
2010's19 (1.35)24.3611
2020's1 (0.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.03 (24.57)
Research Supply Index7.32 (2.92)
Research Growth Index3.93 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (0.87%)5.53%
Reviews69 (4.61%)6.00%
Case Studies41 (2.74%)4.05%
Observational0 (0.00%)0.25%
Other1,374 (91.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]